![]() ![]() Noubar Afeyan, Ph.D., is Co-Founder and Chairman of Tessera Therapeutics and Founder and CEO of Flagship Pioneering. a cofounder of Intellia Therapeutics and a Scientific Advisory Board member at Tessera Therapeutics. Get the latest business insights from Dun & Bradstreet. Its research engine further optimizes the discovered candidates for efficiency, specificity, and fidelity-essentially compressing eons of evolution into a few months. Company Profile Cambridge, MA Competitors, Financials & Contacts - Dun & Bradstreet Find company research, competitor information, contact details & financial data for Tessera Therapeutics, Inc. The company has evaluated tens of thousands of natural and synthetic MGEs to create candidates with the ability to write therapeutic messages into the human genome. McClintock’s contributions to genetics, as well as her intellectual tenacity, agility, and rigor, are an inspiration to everyone at Tessera. Tessera’s gene writer tools are based on nature’s genome architects, Mobile Genetic Elements (MGEs)-the most abundant class of genes across the tree of life, representing approximately half of the human genome. As we write the FutureofGeneticMedicine, we aim to make the broadest possible impact for patients through our LNP delivery. We are honored to launch Tessera Therapeutics close to the 118 th anniversary of Barbara McClintock’s birth. The platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the definitive genetic medicine. Led by Geoffrey von Maltzahn, Ph.D., Co-Founder, Chief Executive Officer, and Board Director, Tessera Therapeutics provides gene writing technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The company intends to use the funds to expand its development efforts. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |